Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Advances in uro-oncology «Oncoforum»: The best of 2011
Journal Information
Vol. 36. Issue 9.
Pages 507-514 (October 2012)
Share
Share
Download PDF
More article options
Visits
1055
Vol. 36. Issue 9.
Pages 507-514 (October 2012)
Special article
Advances in uro-oncology «Oncoforum»: The best of 2011
Avances en uro-oncología «Oncoforum»: lo mejor de 2011
Visits
1055
F. Gómez-Veigaa,
Corresponding author
fgveiga@telefonica.net

Corresponding author.
, A. Alcaraz-Asensiob, J. Burgos-Revillac, J. Cózar-Olmod
a Servicio de Urología, Complejo Hospitalario Universitario de A Corũna, La Corũna, Spain
b Servicio de Urología, Hospital Clínic, Barcelona, Spain
c Servicio de Urología, Hospital Ramón y Cajal, Madrid, Spain
d Servicio de Urología, Hospital Virgen de las Nieves, Granada, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (7)
Table 1. PCa-specific survival (secondary variable) in the PIVOT clinical trial.
Table 2. Results in patients with positive lymph nodes after only RP in a U.S.A. experienced center.
Table 3. Population of patients included in the SWOG 8794 and EORTC 22911 studies.
Table 4. Results of overall survival of the COU-AA-301 clinical trial.
Table 5. Results of the phase I/II clinical trial with MDV3100.
Table 6. Efficacy results of the AXIS study.
Table 7. Histopathological findings in patients with nonseminomatous GCT who underwent retroperitoneal lymphadenectomy, stratified according to the size of the residual tumor.
Show moreShow less
Abstract
Objective

To put forth new findings in urologic oncology with impact in the clinical practice, presented in the principal annual meetings (EAU, ESTRO, AUA, ASCO and ASTRO).

Methods

The reporters of the OncoUrology Forum select and classify the summaries on genitourinary cancer based on the impact on present or future practice. This document includes the summaries having the highest scores.

Results

The OncoUrology Forum committee considered the following messages important. The PIVOT study shows that radical prostatectomy reduces the specific mortality of prostate cancer (PCa) compared to follow-up in observation, in localized high risk PCa or PSA>10ng/mL. Dissection of the pelvic lymph nodes should be done in all the patients with bladder cancer treated by radical cystectomy, regardless of the tumor stage, in accordance with baseline analysis of the Surveillance, Epidemiology and End Results (SEER) data. An analysis of the SEER of patients with renal cancer concluded that the radical nephrectomy is associated to worse cardiovascular and overall survival compared to those treated with partial nephrectomy in localized renal cell carcinoma of ≤2cm. In patients with nonseminomatous germ cells cancer, retroperitoneal lymph node dissection should not be omitted when the residual tumor size is ≤1cm because of the considerably high risk of teratoma and viable cancer.

Conclusions

Although these studies do not offer a final response for all the oncourological subjects, these results will have an impact on the daily clinical practice.

Keywords:
Prostate cancer
Urinary bladder cancer
Kidney cancer
Kidney cancer
Testicular cancer
Penile cancer
Urology
Resumen
Objetivo

Exponer los nuevos hallazgos en urología oncológica con impacto en la práctica clínica presentados en las principales reuniones anuales (EAU, ESTRO, AUA, ASCO y ASTRO).

Métodos

Los informadores del OncoUrology Forum seleccionan y clasifican los resúmenes sobre cáncer genitourinario en función del impacto sobre la práctica clínica presente o futura. Este documento incluye los resúmenes con mayor puntuación.

Resultados

La comisión del OncoUrology Forum consideró importantes los siguientes mensajes. El estudio PIVOT demuestra que la prostatectomía radical reduce la mortalidad específica del cáncer de próstata (CaP), en comparación con seguimiento en observación, en CaP localizado de alto riesgo o PSA>10 ng/ml. La disección de los ganglios linfáticos pélvicos debería hacerse en todos los pacientes con cáncer vesical tratados mediante cistectomía radical, independientemente del estadio tumoral, de acuerdo con un análisis de la base de datos Surveillance, Epidemiology and End Results (SEER). Un análisis de la SEER de pacientes con cáncer renal concluyó que la nefrectomía radical se asocia a peor supervivencia global y cardiovascular, en comparación con la nefrectomía parcial, en carcinoma de células renales localizado y ≤2cm. En pacientes con tumor de células germinales no seminomatoso, no se debe omitir la disección de los ganglios linfáticos retroperitoneales tras quimioterapia cuando el tamãno tumoral residual es ≤1cm, debido al riesgo considerablemente alto de teratoma y cáncer viable.

Conclusiones

Aunque estos estudios no ofrecen una respuesta final para todos los temas oncourológicos, sus resultados tendrán impacto en la práctica clínica diaria.

Palabras clave:
Neoplasia prostática
Neoplasia de la vejiga urinaria
Neoplasia renal
Neoplasia testicular
Neoplasia del pene
Urología

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.acuroe.2021.09.001
No mostrar más